1887

Abstract

Synthetic peptides representing amino acids 156 to 170 of virus capsid protein VP2 from human rhinovirus (HRV) type 2 have previously been used to elicit a neutralizing antibody response; polyclonal antisera against this peptide have been compared with a virusneutralizing monoclonal antibody (8F5) which recognizes the same linear sequence. The neutralizing activity of both antibodies against virus is abolished by an amino acid substitution in VP2 at position 163 but only the peptide antiserum neutralizing activity is affected by a change in VP2 at position 158. The minimal binding site of 8F5 has been mapped, using overlapping peptides, to a sequence TRLNPD covering VP2 residues 160 to 165. Using affinity purification it has been shown that 8 to 10% of total neutralizing activity of polyclonal rabbit or guinea-pig antivirus antiserum is due to recognition of this linear VP2 156 to 170 determinant. Furthermore, a similar population of neutralizing antibodies appears to be associated with an immune response to recent HRV infection in humans. These results confirm the existence of linear determinants on the surface of HRV which may be mimicked by suitable synthetic peptides.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-71-12-3055
1990-12-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/71/12/JV0710123055.html?itemId=/content/journal/jgv/10.1099/0022-1317-71-12-3055&mimeType=html&fmt=ahah

References

  1. Appleyard G., Russell S. M., Clarke B. E., Speller S. A., Trowbridge M., Vadolas J. 1990; Neutralization epitopes of human rhinovirus type 2. Journal of General Virology 71:1275–1282
    [Google Scholar]
  2. Cambiaso C. L., Goffinet A., Vaerman J.-P., Heremans J. F. 1975; Glutaraldehyde-activated aminohexyl derivative of Sepharose 4B as a new versatile immunosorbent. Immunochemistry 12:273–278
    [Google Scholar]
  3. Francis M. J., Hastings G. Z., Sangar D. V., Clark R. P., Syred A., Clarke B. E., Rowlands D. J., Brown F. 1987a; A synthetic peptide which elicits neutralizing antibody against human rhinovirus type 2. Journal of General Virology 68:2687–2691
    [Google Scholar]
  4. Francis M. J., Fry C. M., Rowlands D. J., Bittle J. L., Houghton R. A., Lerner R. A., Brown F. 1987b; Immune response to uncoupled peptides of foot-and-mouth disease virus. Immunology 60:1–6
    [Google Scholar]
  5. Mccullough K. C., Crowther J. R., Butcher R. N. 1985; Alteration in antibody reactivity with foot-and-mouth disease virus (FMDV) 146S antigen before and after binding to a solid phase or complexing with specific antibody. Journal of Immunological Methods 82:91–100
    [Google Scholar]
  6. Mendappa K. C., Mclean C., Rueckert R. R. 1971; On the structure of rhinovirus 1A. Virology 44:259–270
    [Google Scholar]
  7. Rossmann M. G., Arnold E., Erickson J. W., Frankenberger E. A., Griffith J. P., Hecht H.-J., Johnson E., Kramer G., Luo M., Mosser A. G., Rueckert R. R., Sherry B., Vriend G. 1985; Structure of a human common cold virus and functional relationship to other picomaviruses. Nature; London: 317145–153
    [Google Scholar]
  8. Rueckert R. R. 1976; On the structure and morphogenesis of picomaviruses. In Comprehensive Virology 6 pp. 131–213 Fraenkel-Conrat H., Wagner R. R. Edited by New York: Plenum Press;
    [Google Scholar]
  9. Sherry B., Mosser A. G., Colonno R. J., Rueckert R. R. 1986; Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14. Journal of Virology 57:246–257
    [Google Scholar]
  10. Skern T., Neubauer C., Frasel L., Gründler P., Sommergruber W., Zorn M., Kuechler E., Blaas D. 1987; A neutralizing epitope on human rhinovirus type 2 includes amino acid residues between 153 and 164 of virus capsid protein VP2. Journal of General Virology 68:315–323
    [Google Scholar]
  11. Stott E. J., Killington R. A. 1972; Rhinoviruses. Annual Review of Microbiology 26:503–524
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-71-12-3055
Loading
/content/journal/jgv/10.1099/0022-1317-71-12-3055
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error